The medical technology startup Science Corporation, founded in 2021 by former President Neuralink Max Hodak, has announced that the company has completed a $400 million Series D financing round.
An informed source told TechCrunch that the valuation of the company in this round of financing is $3.5 billion. The institutions participating in this round of investment include Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
Hodak managed to gain access to a graduate neuroscience laboratory during his university years and has since been engaged in biotechnology research. He co-founded Science with others, with the aim of using new technologies to understand and interact with the brain.
Science's first product is PRIMA, which is a wearable, implantable chip that helps patients with age-related macular degeneration to regain some vision. This device has been approved in Europe and is already on the market in Germany, while trials are also underway for new indications.
Hodak stated at the TechCrunch Disrupt site that the device is currently undergoing trials for another disease that can lead to blindness – Stargardt.
With this financing, the company hopes to bring this device to the United States through the Humanitarian Device Exemption of FDA. This mechanism allows experimental medical technologies to be used for the treatment of rare diseases. Science has convinced FDA that late-stage macular degeneration in both eyes is rare enough to justify seeking approval for the use of this device in the United States.
However, the ambitious vision and original purpose of this startup company is to directly connect the human brain through a bio-hybrid sensor made by combining cultured neurons with silicon materials. The company is currently working with neurosurgery professors from Yale University, Murat G and nel, to design preliminary human trials for this device. Gü nel told TechCrunch that this technology could potentially provide treatment options for Parkinson's disease, as well as other brain injuries and diseases.












